Content
Gilead Sciences Stock Approaches Daily Buying Area
Article By:
Elliottwave Forecast
Read
Monday, February 12, 2024 7:16 AM EDT
Gilead Sciences, Inc. is an US American biopharmaceutical company. It focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir and sofosbuvir.
In this article: GILD
Week In Review: I-Mab Morphs Into US-Only Company; Sells China Assets For $80 Million
Article By:
ChinaBio® Today
Read
Sunday, February 11, 2024 12:40 PM EDT
I-Mab will become a completely US-based company, divesting itself of I-Mab Biopharma (Hangzhou), an unconsolidated affiliate. I-Mab Hangzhou will acquire rights to I-Mab’s drug assets in Greater China for $80 million.
LLY Vs NVO: Which One Is Likely To Become A $1T Company First
Article By:
The Tokenist
Read
Thursday, February 8, 2024 5:06 AM EDT
Tackling growing waistlines is expected to yield much shareholder value.
MicroMarvel - ORIC Pharmaceutical - Fights Cancer
Article By:
Jim Van Meerten
Read
Wednesday, February 7, 2024 2:12 PM EDT
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of cancers in the United States.
In this article: ORIC
Fusion Pharmaceuticals - Already Discovered By Wall Street
Article By:
Jim Van Meerten
Read
Tuesday, February 6, 2024 2:07 PM EDT
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States.
In this article: FUSN
MicroMarvel: MacroGenics Confuses Wall Street
Article By:
Jim Van Meerten
Read
Monday, February 5, 2024 11:29 AM EDT
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States.
In this article: MGNX
Week In Review: Shanghai Inmagene Signs $230 Million Deal To Develop Two HutchMed Immunology Assets
Article By:
ChinaBio® Today
Read
Saturday, February 3, 2024 2:40 PM EDT
Inmagene Biopharma of Shanghai transferred 7.5% of its shares to HutchMed for global rights to two clinical stage immunology assets. It will also be responsible for up to $230 million in milestones.
Tarsus Pharmaceuticals - Mixed Projections
Article By:
Jim Van Meerten
Read
Friday, February 2, 2024 11:36 AM EDT
Tarsus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions.
In this article: TARS
Week In Review: Arrivent BioPharma Raises $175 Million In IPO For In-Licensings From China
Article By:
ChinaBio® Today
Read
Saturday, January 27, 2024 1:40 PM EDT
ArriVent BioPharma priced its upsized Nasdaq IPO at $18 dollars per share, raising $175 million. The company’s stated goal is to find promising novel assets from China and other countries, which it aims to bring to the US market.
Chart Of The Day: Summit Therapeutics Begins To Soar
Article By:
Jim Van Meerten
Read
Thursday, January 25, 2024 8:24 PM EDT
Summit Therapeutics Inc., a biopharmaceutical company, researches and develops primarily oncology therapies in the United States and the United Kingdom.
In this article: SMMT
MicroMarvel Neurogene Challenges Big Pharma
Article By:
Jim Van Meerten
Read
Monday, January 22, 2024 6:01 PM EDT
Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases.
In this article: NGNE